GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » EBIT per Share

CODX (Co-Diagnostics) EBIT per Share : $-1.24 (TTM As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics EBIT per Share?

Co-Diagnostics's EBIT per Share for the three months ended in Mar. 2025 was $-0.27. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Co-Diagnostics's EBIT per Share or its related term are showing as below:

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Co-Diagnostics was -1.50% per year. The lowest was -40.70% per year. And the median was -32.60% per year.

CODX's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Co-Diagnostics's EBIT for the three months ended in Mar. 2025 was $-8.55 Mil.


Co-Diagnostics EBIT per Share Historical Data

The historical data trend for Co-Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics EBIT per Share Chart

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.49 1.54 -0.37 -1.46 -1.32

Co-Diagnostics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.26 -0.34 -0.39 -0.27

Co-Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Co-Diagnostics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-40.081/30.335
=-1.32

Co-Diagnostics's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

EBIT per Share(Q: Mar. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-8.552/32.049
=-0.27

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Co-Diagnostics  (NAS:CODX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Co-Diagnostics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Executives
Brian Lee Brown officer: Chief Financial Officer 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy director 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan director, officer: CEO and President 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson director 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson officer: CFO and Secretary 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield director, officer: Chief Science Officer 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc 10 percent owner 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner director 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc 10 percent owner 8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc 10 percent owner 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124